Angiodynamics Inc (ANGO) 14.50 $ANGO
Can AngioDynamics' (ANGO) Q4 Earnings Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:25AM CDT
AngioDynamics Inc (ANGO) is set to report fourth-quarter fiscal 2016 results on Jul 13.
PMC: 25.64 (+0.83), LH: 135.30 (+3.33), ANGO: 14.50 (+0.11), COO: 181.83 (+3.33)
Angiodynamics Shares Up 23.4% Since SmarTrend's Buy Recommendation (ANGO)
Comtex SmarTrend(R) - Wed Jun 29, 1:54PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 4 months, Angiodynamics has returned 23.39% as of today's recent price of $14.06.
ANGO: 14.50 (+0.11)
PAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Apr 28, 11:09AM CDT
What:
PAVMU: 13.40 (-0.10), ANGO: 14.50 (+0.11), NDAQ: 65.88 (+0.96)
AngioDynamics Tops Q3 Earnings, Sales; FY16 View Pruned
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 9:00AM CDT
AngioDynamics Inc. (ANGO) reported adjusted earnings of 15 cents per share in the third quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a couple cents.
LMAT: 13.70 (+0.14), AMAG: 25.19 (-0.18), ANGO: 14.50 (+0.11), OFIX: 46.70 (+1.09)
Natus Medical: A Strong Sell on Weak Q1 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 12:00PM CDT
On Apr 7, Zacks Investment Research downgraded Natus Medical Inc (BABY) to a Zacks Rank #5 (Strong Sell).
BABY: 39.65 (+0.57), GMED: 24.87 (+0.42), ARAY: 5.19 (+0.29), ANGO: 14.50 (+0.11)
Mazor Robotics Receives 5 Orders in Q1, Shares Down
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 12:20PM CDT
Shares of Mazor Robotics Ltd. (MZOR) fell 4.1% to close at $11.60 on Apr 5, after the company announced the receipt of five orders for Renaissance system.
GMED: 24.87 (+0.42), MZOR: 20.50 (+1.21), ARAY: 5.19 (+0.29), ANGO: 14.50 (+0.11)
Downgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Apr 06, 3:16AM CDT
Angiodynamics (NASDAQ:ANGO) was downgraded from Buy to Hold at Canaccord Genuity today. The stock closed yesterday at $11.07 on volume of 222,000 shares, above average daily volume of 75,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
ANGO: 14.50 (+0.11)
Can the Uptrend Continue for AngioDynamics (ANGO)?
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:49AM CDT
Investors certainly have to be happy with AngioDynamics, Inc. (ANGO) and its short term performance
ANGO: 14.50 (+0.11)
AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer
GlobeNewswire - Mon Apr 04, 7:00AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of James C. Clemmer as the company's new President and Chief Executive Officer, effective April 4, 2016.
ANGO: 14.50 (+0.11)
AngioDynamics to Report Fiscal 2016 Third Quarter Financial Results
GlobeNewswire - Tue Mar 29, 5:30AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 third quarter ended February 29, 2016, on Thursday, April 7, 2016, after the close of the U.S. financial markets.
ANGO: 14.50 (+0.11)
Inogen (INGN) Q4 Earnings: A Surprise in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 9:50AM CST
Inogen Inc. (INGN) is scheduled to report fourth-quarter 2015 earnings on Mar 14.
EW: 104.72 (+0.97), INGN: 51.91 (-0.49), LMNX: 21.66 (+0.46), ANGO: 14.50 (+0.11)
AngioDynamics and Merz North America Establish Multi-Year Relationship to Market Asclera for Vein Patients
GlobeNewswire - Thu Mar 10, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that they have signed an agreement with Merz North America, U.S. affiliate of the global Merz Pharma Group, to serve as the exclusive distributor of Asclera(R) (polidocanol) Injection within the vein market in the U.S.
ANGO: 14.50 (+0.11)
AngioDynamics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 07, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to participate in a Q&A session at the Barclays Global Healthcare Conference on Thursday, March 17, 2016, at 8:00 a.m. ET. The conference will be held at the Loews Miami Beach Hotel in Miami, FL.
ANGO: 14.50 (+0.11)
AngioDynamics: Health Canada Okays Celerity with Navigation
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:20PM CST
AngioDynamics (ANGO) recently announced that Health Canada has approved the company's Celerity PICC Tip Confirmation System with Navigation.
ABMD: 114.15 (+0.62), EXAC: 27.12 (+0.51), LMNX: 21.66 (+0.46), ANGO: 14.50 (+0.11)
Mauna Kea Technologies Announces the Appointment of Joseph DeVivo as a Non-Executive Director
PR Newswire - Mon Jan 11, 11:00AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Joseph M. DeVivo as a Director. Mr. DeVivo is the President and Chief Executive Officer of AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.
ANGO: 14.50 (+0.11)
AngioDynamics Q2 Earnings In Line, Sales Top; '16 View Cut
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:20AM CST
AngioDynamics (ANGO) reported adjusted earnings of 14 cents per share in the second quarter of fiscal 2016, which were in line with the Zacks Consensus Estimate but down 17.6% on a year-over-year basis.
CAPR: 4.02 (-0.07), NXTM: 22.91 (+1.07), ABAX: 50.95 (+2.54), ANGO: 14.50 (+0.11)
AngioDynamics Reports Fiscal 2016 Second Quarter Results
GlobeNewswire - Thu Jan 07, 3:01PM CST
-- Net sales of $89.2 million
ANGO: 14.50 (+0.11)
AngioDynamics to Present at the 34th Annual J.P. Morgan Global Healthcare Conference
GlobeNewswire - Mon Jan 04, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph DeVivo, President and Chief Executive Officer, is scheduled to present at the 34 Annual J.P. Morgan Global Healthcare Conference on Wednesday, January 13, 2016, at 5:30 p.m. EST. The conference will be held at the Westin St. Francis in San Francisco, Ca.
JPM: 61.83 (+1.25), ANGO: 14.50 (+0.11)
AngioDynamics to Report Fiscal 2016 Second Quarter Financial Results
GlobeNewswire - Mon Dec 28, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 second quarter ended November 30, 2015, on Thursday, January 7, 2016, after the close of the U.S. financial markets.
ANGO: 14.50 (+0.11)
A Change in Tides - Analyst Notes on Hemisphere Media Group, AngioDynamics, ChemoCentryx and Catalyst Pharmaceuticals
ACCESSWIRE - Thu Dec 17, 6:55AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hemisphere Media Group Inc. (NASDAQ: HMTV), AngioDynamics Inc. (NASDAQ: ANGO), ChemoCentryx Inc. (NASDAQ: CCXI) and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CPRX: 0.80 (+0.03), HMTV: 12.02 (+0.24), CCXI: 4.80 (-0.02), ANGO: 14.50 (+0.11)
Can AngioDynamics' (ANGO) Q4 Earnings Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:25AM CDT
AngioDynamics Inc (ANGO) is set to report fourth-quarter fiscal 2016 results on Jul 13.
PMC: 25.64 (+0.83), LH: 135.30 (+3.33), ANGO: 14.50 (+0.11), COO: 181.83 (+3.33)
Angiodynamics Shares Up 23.4% Since SmarTrend's Buy Recommendation (ANGO)
Comtex SmarTrend(R) - Wed Jun 29, 1:54PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 4 months, Angiodynamics has returned 23.39% as of today's recent price of $14.06.
ANGO: 14.50 (+0.11)
PAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Apr 28, 11:09AM CDT
What:
PAVMU: 13.40 (-0.10), ANGO: 14.50 (+0.11), NDAQ: 65.88 (+0.96)
AngioDynamics Tops Q3 Earnings, Sales; FY16 View Pruned
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 9:00AM CDT
AngioDynamics Inc. (ANGO) reported adjusted earnings of 15 cents per share in the third quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a couple cents.
LMAT: 13.70 (+0.14), AMAG: 25.19 (-0.18), ANGO: 14.50 (+0.11), OFIX: 46.70 (+1.09)
Natus Medical: A Strong Sell on Weak Q1 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 12:00PM CDT
On Apr 7, Zacks Investment Research downgraded Natus Medical Inc (BABY) to a Zacks Rank #5 (Strong Sell).
BABY: 39.65 (+0.57), GMED: 24.87 (+0.42), ARAY: 5.19 (+0.29), ANGO: 14.50 (+0.11)
Mazor Robotics Receives 5 Orders in Q1, Shares Down
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 12:20PM CDT
Shares of Mazor Robotics Ltd. (MZOR) fell 4.1% to close at $11.60 on Apr 5, after the company announced the receipt of five orders for Renaissance system.
GMED: 24.87 (+0.42), MZOR: 20.50 (+1.21), ARAY: 5.19 (+0.29), ANGO: 14.50 (+0.11)
Downgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Apr 06, 3:16AM CDT
Angiodynamics (NASDAQ:ANGO) was downgraded from Buy to Hold at Canaccord Genuity today. The stock closed yesterday at $11.07 on volume of 222,000 shares, above average daily volume of 75,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
ANGO: 14.50 (+0.11)
Can the Uptrend Continue for AngioDynamics (ANGO)?
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:49AM CDT
Investors certainly have to be happy with AngioDynamics, Inc. (ANGO) and its short term performance
ANGO: 14.50 (+0.11)
AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer
GlobeNewswire - Mon Apr 04, 7:00AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of James C. Clemmer as the company's new President and Chief Executive Officer, effective April 4, 2016.
ANGO: 14.50 (+0.11)
AngioDynamics to Report Fiscal 2016 Third Quarter Financial Results
GlobeNewswire - Tue Mar 29, 5:30AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 third quarter ended February 29, 2016, on Thursday, April 7, 2016, after the close of the U.S. financial markets.
ANGO: 14.50 (+0.11)
Inogen (INGN) Q4 Earnings: A Surprise in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 9:50AM CST
Inogen Inc. (INGN) is scheduled to report fourth-quarter 2015 earnings on Mar 14.
EW: 104.72 (+0.97), INGN: 51.91 (-0.49), LMNX: 21.66 (+0.46), ANGO: 14.50 (+0.11)
AngioDynamics and Merz North America Establish Multi-Year Relationship to Market Asclera for Vein Patients
GlobeNewswire - Thu Mar 10, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that they have signed an agreement with Merz North America, U.S. affiliate of the global Merz Pharma Group, to serve as the exclusive distributor of Asclera(R) (polidocanol) Injection within the vein market in the U.S.
ANGO: 14.50 (+0.11)
AngioDynamics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 07, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to participate in a Q&A session at the Barclays Global Healthcare Conference on Thursday, March 17, 2016, at 8:00 a.m. ET. The conference will be held at the Loews Miami Beach Hotel in Miami, FL.
ANGO: 14.50 (+0.11)
AngioDynamics: Health Canada Okays Celerity with Navigation
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:20PM CST
AngioDynamics (ANGO) recently announced that Health Canada has approved the company's Celerity PICC Tip Confirmation System with Navigation.
ABMD: 114.15 (+0.62), EXAC: 27.12 (+0.51), LMNX: 21.66 (+0.46), ANGO: 14.50 (+0.11)
Mauna Kea Technologies Announces the Appointment of Joseph DeVivo as a Non-Executive Director
PR Newswire - Mon Jan 11, 11:00AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Joseph M. DeVivo as a Director. Mr. DeVivo is the President and Chief Executive Officer of AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.
ANGO: 14.50 (+0.11)
AngioDynamics Q2 Earnings In Line, Sales Top; '16 View Cut
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:20AM CST
AngioDynamics (ANGO) reported adjusted earnings of 14 cents per share in the second quarter of fiscal 2016, which were in line with the Zacks Consensus Estimate but down 17.6% on a year-over-year basis.
CAPR: 4.02 (-0.07), NXTM: 22.91 (+1.07), ABAX: 50.95 (+2.54), ANGO: 14.50 (+0.11)
AngioDynamics Reports Fiscal 2016 Second Quarter Results
GlobeNewswire - Thu Jan 07, 3:01PM CST
-- Net sales of $89.2 million
ANGO: 14.50 (+0.11)
AngioDynamics to Present at the 34th Annual J.P. Morgan Global Healthcare Conference
GlobeNewswire - Mon Jan 04, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph DeVivo, President and Chief Executive Officer, is scheduled to present at the 34 Annual J.P. Morgan Global Healthcare Conference on Wednesday, January 13, 2016, at 5:30 p.m. EST. The conference will be held at the Westin St. Francis in San Francisco, Ca.
JPM: 61.83 (+1.25), ANGO: 14.50 (+0.11)
AngioDynamics to Report Fiscal 2016 Second Quarter Financial Results
GlobeNewswire - Mon Dec 28, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 second quarter ended November 30, 2015, on Thursday, January 7, 2016, after the close of the U.S. financial markets.
ANGO: 14.50 (+0.11)
A Change in Tides - Analyst Notes on Hemisphere Media Group, AngioDynamics, ChemoCentryx and Catalyst Pharmaceuticals
ACCESSWIRE - Thu Dec 17, 6:55AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hemisphere Media Group Inc. (NASDAQ: HMTV), AngioDynamics Inc. (NASDAQ: ANGO), ChemoCentryx Inc. (NASDAQ: CCXI) and Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CPRX: 0.80 (+0.03), HMTV: 12.02 (+0.24), CCXI: 4.80 (-0.02), ANGO: 14.50 (+0.11)
